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Abstract
Molecular characterization of breast cancer is pivotal for identifying new molecular targets and determining the
appropriate treatment choices. Advances in molecular proﬁling technology have given greater insight into this het-
erogeneous disease, over and above hormone receptor and human epidermal growth factor receptor 2 status. Agents
targeting recently characterized molecular biomarkers are under clinical development; the success of these targeted
agents is likely to depend on identifying the patient population most likely to beneﬁt. Therefore, clinical trials of breast
cancer often require prescreening for, or stratiﬁcation by, relevant molecular markers or exploratory analyses of
biomarkers that can predict or monitor the response to treatment. Consequently, the role of the pathologist has
become increasingly important. The key considerations for pathologists include tissue availability, ownership of
archival tissue, type of diagnostic/biomarker test required, method of sample processing, concordance between
different tests and testing centers, and tumor heterogeneity. In the present review, we explore how pathology is used
in current clinical trials of breast cancer and describe the various technologies available for molecular testing.
Furthermore, the factors required for the successful application of pathology in clinical trials of breast cancer and the
issues that can arise and how these can be circumvented are discussed.
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Breast cancer constitutes one of the most common types of cancer,
affecting approximately 232,670women and 2360men in theUnited
States in 2014.1 It is also the second most common cause of cancer
death in women.1 The heterogeneous nature of breast cancer, in both
clinical pathologic and histologic examination, has long since repre-
sented a challenge to identifying the appropriate treatment for pa-
tients with this disease.2 Traditionally, breast cancer tumors were
classiﬁed according to the histologic features and slide-based tech-
niques that categorized breast tumors as ductal or lobular carcinoma
and determined the nodal status, size, and grade of the tumor.3,4
During the past decade or so, with advances in molecular gen-
otyping technologies, several molecular subtypes of breast cancer
have been identiﬁed, dependent on hormone receptor (HR) and1Department of Women’s Oncology
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differ in prognosis and chemotherapy responsiveness (Table 1).
The vast majority of breast cancers are epithelial carcinomas and
therefore are the focus of the present review. Broadly speaking, the
main intrinsic subtypes of epithelial breast cancer include luminal A,
luminal B, HER2þ, and basal-like cancer.2,5-8,13-16 Further subtypes
based on androgen receptor (AR) status have also been proposed.13
The identiﬁcation of speciﬁc molecular subtypes of breast cancer
has paved the way for a more personalized approach to the treatment
of breast cancer using targeted therapies. Moreover, the clinical
beneﬁt observed with agents targeting hormone signaling or HER2
has conﬁrmed the importance of identifying further molecular targets.
Advances in molecular proﬁling have recently unveiled several genetic
and epigenetic alterations that are likely drivers of breast tumor
biology.7 Some of these genetic alterations can help distinguish the
current molecular subtypes of breast cancer (Table 1), and others can
form their own molecular class, such as phosphatidylinositol 3-kinase
(PI3K) pathway aberrations, which are present at high frequencies
across all current molecular subtypes.7
Additional molecularly targeted agents for breast cancer are now
in clinical development. The success of these new, targeted thera-
peutic agents will depend on identifying the patient populations
most likely to respond and on characterizing biomarkers that can. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Table 1 Molecular Subtypes of Breast Cancer Tumors5-12
Molecular
Feature HRD (ERD and/or PRD) HER2D TNBC (HRL, HER2L)
Typical intrinsic
subtype
Luminal A (HER2) Luminal B (HER2þ/) HER2 Basal
Frequency among
breast cancers
40%-60% w15% w10% 10%-25%
Genetic proﬁle Low expression of proliferative
genes (eg, Ki-67); high expression
of ESR1, GATA3, FOXA1, XBP1,
and cMYB; frequent mutation of
MAP3K1 and MAP2K4
Lower expression of ER-related
genes; increased expression of
proliferation genes; frequent
ampliﬁcation of CCND1 (cyclin D);
fusion of ESR1 and CCDC170
genes
High expression of HER2 and
related genes; increased expression
of proliferation genes; high genomic
instability; frequent TP53 mutations
Expression of genes characteristic
of normal breast myoepithelial cells
(eg, cytokeratins 5, 6, and 17);
high expression of DNA repair
proteins; frequent TP53 mutations;
often BRCA1 mutant
Grade Lower (moderately to well
differentiated)
Higher (poorly to moderately
differentiated)
High (poorly differentiated) High (poorly differentiated)
Prognosis Good Intermediate Generally poor Generally poor
Targeted therapy Endocrine (tamoxifen, letrozole,
anastrozole, exemestane,
fulvestrant)
Endocrine (tamoxifen, letrozole,
anastrozole, exemestane,
fulvestrant)
Anti-HER2 (trastuzumab,
pertuzumab, T-DM1, lapatinib)
Agents targeting DNA repair are
under investigation (eg, PARP
inhibitors)
Chemotherapy Lower response Intermediate response Responds to anthracycline-based
chemotherapy
Responds to platinum-based
chemotherapy
Abbreviations: BRCA1 ¼ breast cancer 1, early onset; CCDC170 ¼ coiled-coil domain containing 170; ERþ ¼ estrogen receptor-positive; ESR1 ¼ estrogen receptor 1; HER2þ/ ¼ human
epidermal growth factor receptor 2-positive/negative; HRþ/ ¼ hormone receptor-positive/negative; MAP2K4 ¼ mitogen-activated protein kinase 4; MAP3K1 ¼ mitogen-activated protein kinase 1;
PARP ¼ poly ADP ribose polymerase; PRþ ¼ progesterone receptor-positive; T-DM1 ¼ trastuzumab emtansine; TNBC ¼ triple-negative breast cancer; TP53 ¼ tumor protein 53.monitor the response to treatment. As such, the role of the
pathologist in clinical trials of breast cancer is changing from a
primarily histologic/cytologic diagnostic role to a critical role in
analyzing molecular biomarkers and the changing molecular proﬁle
of the cancer during treatment. In addition, the need for sufﬁcient
material for molecular proﬁling and for repeated analyses during the
course of treatment has expanded the types of tissue examined by
the pathologist, and with it, the pathologist’s repertoire of tools and
techniques.
The present review provides an overview of how pathology is
being used in breast cancer trials, including the available and novel
techniques used in molecular testing of breast cancer. We also
discuss the key technical and legal considerations required to execute
well-designed clinical trials that can improve our understanding of
the etiology and treatment of breast cancer.
Molecular Testing in Breast Cancer
Molecular testing in breast cancer can be used to diagnose tumor
types, recognize hereditary implications (eg, BRCA1 mutations),
identify appropriate therapeutic agents (eg, HER2þ disease),
determine the prognosis of the disease, and identify biomarkers that
can predict or monitor the response to treatment.17,18 The major
techniques used in molecular testing in breast cancer trials are
summarized in Table 2.
Immunohistochemistry and Cytogenetics
HER2 is a clear prognostic marker and therapeutic target for
breast cancer, and accurate assessment of HER2 status is critical for
the optimal treatment of patients.18 The techniques for diagnosing
HER2þ breast tumors are primarily based on immunohistochem-
istry (IHC) and ﬂuorescence in situ hybridization (FISH), both of
which can be automated and allow for concurrent assessment of
tumor morphology, minimizing the appearance of artefacts.18,32HER2 testing is standard practice in breast cancer diagnosis, and
the IHC and FISH assays have both received approval by the US
Food and Drug Administration (FDA) for predicting clinical
response to anti-HER2 therapy.32 According to the American So-
ciety of Clinical Oncology (ASCO)/College of American Patholo-
gists (CAP) guidelines, HER2þ status is deﬁned when tumor
specimens demonstrate either strong complete membrane staining
in > 10% of contiguous and homogenous tumor cells by IHC
(IHC3þ) or a HER2 copy number of  6.0 signals/cell or
HER2/chromosome 17 centromere (CEP17) ratio of  2.0 using in
situ hybridization techniques (ISH; based on counting 20 cells
within the area).33
IHC is the standard method used for evaluating HR status, and a
tumor with  1% of the cells with estrogen receptor (ER) and/or
progesterone receptor (PR) is considered ERþ and/or PRþ.34,35
Owing to the particular nuclear staining of ER, the detection of
HR positivity with IHC is subject to less interobserver variability
than is the identiﬁcation of HER2 status.36 The IHC4 prognostic
score combines the IHC results for HER2, ER, PR, and the pro-
liferation marker Ki-67, and is a simple and cost-effective method to
assess the breast cancer subtype and prognosis.27,37
Advances in sample preparation, microscopy, and image analysis
have enhanced IHC and FISH methods. Bright-ﬁeld ISH methods
that can be performed using regular light microscopy, such as
chromogenic ISH (CISH), silver ISH (SISH), and dual
ISH (a combination of CISH and SISH techniques), have also been
developed to overcome the limitations of dark-ﬁeld ﬂuorescence
microscopy and the lack of morphologic details associated with
FISH.38,39 These methods might also be able to evaluate HER2
heterogeneity more accurately.38 In addition, digital microscopy and
image analysis technologies are becoming increasingly important
tools in pathology. For example, computerized image analysis has
been shown to help improve the accuracy and reliability of IHC, inClinical Breast Cancer June 2016 - 167
Table 2 Molecular Assays Used in Breast Cancer Clinical Trials
IHC19-21 FISH20 RT-PCR22,23
DNA Hybridization-Based
Analysis24,25 NGS26
Description
Use of antibodies to detect
levels of a speciﬁc protein
Use of a ﬂuorescently labelled
DNA probe to detect speciﬁc
DNA sequences
Conversion of RNA to cDNA by
reverse transcriptase then
quantiﬁcation of speciﬁc gene
sequences using PCR
Detection of speciﬁc DNA
sequences or cDNAs (for RNA
analysis) by hybridization to an
array of DNA probes
Sequencing of thousands or
millions of DNA sequences in
1 reaction
Detection
Protein expression levels Gene copy number alterations,
DNA rearrangements
Gene expression levels Gene copy number alterations,
DNA rearrangements, speciﬁc
SNPs (DNA); gene expression
levels, alternative splicing, RNA
editing (cDNA)
Gene copy number alterations,
DNA rearrangements, mutations
(DNA-seq); gene expression
levels, splicing patterns,
RNA editing (RNA-seq)
Example assays
IHC427 HER2 FISH pharmDX Kit,
PathVysion HER2 DNA
Probe Kit28
Oncotype DX, PAM50, Breast
Cancer Index, EndoPredict29
Gene expression assays include:
MammaPrint, Prosigna, Genomic
Grade Index29,30
Examples of NGS panels include
FoundationOne, TruSight
Cancer, UW-OncoPlex,
GeneRead DNAseq Human
Comprehensive Cancer Panel,
Ion AmpliSeq Comprehensive
Cancer Panel31
Sample requirement
Tissue sections; typically cut
from FFPE samples;
phosphorylated epitopes
might instead require snap
freezing and alcohol ﬁxation
Tissue sections; typically
cut from FFPE samples
FFPE samples, fresh frozen
specimens
As low as 75 ng DNA from
FFPE sample for some
applications; or DNA from fresh
frozen tissue specimens
10-300 ng input DNA/RNA
depending on the DNA/RNA
quality and assay type; NGS
panels typically require > 100 ng
DNA (w40 mM FFPE material);
DNA/RNA from fresh frozen
specimens more ideal
Advantages
Simple, inexpensive
procedure; processed slides
can be stored for years and
reassessed; cell morphology
can be viewed in parallel
High sensitivity and speciﬁcity;
reproducible; quantitative and
objective score
Low cost, rapid results, sensitive
and quantitative with real-time
PCR
Ability to assay all regions in
the genome in a cost-effective
manner
Low cost per base pair; highly
sensitive and quantitative; ability
to assay all genes/mutations in
the genome, including rare
sequences
Disadvantages
Issues with reproducibility;
semiquantitative, subjective
score; ﬁxation time can
affect results; results
dependent on quality of
antibody used to detect the
protein; usually only 1-2
proteins can be analyzed
per section
Labor intensive; costly
ﬂuorescence microscope
required; results must be
captured and stored within a
short period (ﬂuorescent signal
decays within a few weeks); only
1-2 DNA regions analyzed per
experiment
Requires knowledge of candidate
genes, no sequence information,
can be issues with variability and
cross-test comparison
Semiquantitative; dependent
on the sensitivity and speciﬁcity
of the probes; lower base pair
resolution than sequencing; rare
sequences not necessarily
detected
Quantity of information not
always required; costly per
patient; complicated data
analysis; length of time (weeks)
for results; DNA/RNA quality not
always sufﬁcient from
FFPE samples
Abbreviations: cDNA ¼ complementary DNA; DNA-seq ¼ DNA-sequencing; FFPE ¼ formalin-ﬁxed parafﬁn-embedded; FISH ¼ ﬂuorescent in situ hybridization; HER2 ¼ human epidermal growth
factor receptor 2; IHC ¼ immunohistochemistry; NGS ¼ next-generation sequencing; PAM50 ¼ prediction analysis of microarray 50; PCR ¼ polymerase chain reaction; RNA-seq ¼ RNA-
sequencing; RT ¼ reverse transcription; SNP ¼ single nucleotide polymorphism.
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168 -particular, in the diagnosis of HRþ and/or HER2þ tumors.36
Examples of computerized image analysis platforms include the
Aperio ScanScope (Aperio, Vista, CA) and the Deﬁniens (Munich,
Germany) Tissue Studio. The Aperio ScanScope system allows the
scanning of whole glass slides to create a digital image that can be
analyzed using speciﬁc algorithms within a short period.36 The
Deﬁniens Tissue Studio system detects regions of interest and
distinguishes cells and subcellular attributes within the target
regions (eg, cell membrane for HER2 analysis or nucleus for HR
analysis).36 In addition, tissue microarrays are a high-throughput
method that allows multiple analyses to be performed for mul-
tiple patients on a single microscope slide.34,40 Up toClinical Breast Cancer June 2016approximately 1000 tissue samples can be arrayed into a single
parafﬁn block and IHC or FISH performed simultaneously on
multiple samples and under identical conditions.34,40 The high-
precision tissue microarray instrument (typically Beecher In-
struments, Sun Prairie, WI) acquires tissue cores from predeﬁned
regions of donor tissue sample parafﬁn blocks and places them at
precise coordinates on an empty recipient block.40 Small sections
(5 mm) can be cut from the tissue microarray blocks to generate
tissue microarray slides for molecular and IHC analyses. This
technology enables simultaneous analysis of multiple targets at
the DNA, RNA, and protein levels on a large number of speci-
mens. It also allows for experimental uniformity and helps
Hyo Sook Han, Anthony M. Maglioccoconserve valuable archival tissue samples.40 Taken together, such
advances can improve workﬂow efﬁciency and yield more ac-
curate results, leading to an increased role for the pathologist in
diagnostics and personalized medicine.
Genomic Techniques
Several different techniques are available to assay a group of genes
at once. Oncotype DX (Genomic Health Inc.) is a quantitative
reverse transcription-polymerase chain reaction (RT-PCR) assay that
measures the expression of 21 genes (16 cancer-related genes and 5
reference genes that serve as internal controls).41 This assay was
developed to provide a Recurrence Score in women with tamoxifen-
treated, lymph node-negative, ERþ early-stage breast cancer and has
been optimized for formalin-ﬁxed parafﬁn-embedded tumor sam-
ples.41 The 21 genes are derived from a set of 250 genes likely to be
prognostic for HRþ breast cancer.37 The Kaplan-Meier estimates of
the rates of distant recurrence at 10 years in patients with low ( 17),
intermediate (18-30), and high ( 31) Recurrence Scores were
shown to be 7%, 14%, and 31%, respectively.41Women with a high-
risk score have been shown to beneﬁt from adjuvant chemotherapy,
but those with a low-risk score derive minimal beneﬁt from
chemotherapy.42 However, although HER2, ER, and PR genes are
part of the 21-gene set,41 the HER2 and HR status should be
independently assessed.43 To date, Oncotype DX is the only mul-
tigene breast cancer assay recommended by the main breast cancer
management guidelines for its use as a prognostic test and its ability to
predict the likelihood of adjuvant chemotherapy beneﬁt in node-
negative, ERþ, HER2 early-stage breast cancer.44-47 Although the
Oncotype DX assay has become the most widely used clinical gene
expression assay in the United States, similar prognostic information
was found to be provided by the IHC4 score,27 which is a simpler and
less expensive alternative.37
MammaPrint (Agendia) is a DNAmicroarray-based 70-gene assay,
which involves hybridization of complementary DNA to speciﬁc
probes to determine the gene expression levels.48 The test was
developed using breast cancer specimens from women who had un-
dergone surgery but had received no systemic therapy for primary
breast cancer and had been followed up for 5 years.48 The 70 genes
were selected from a microarray of 25,000 genes.48 Using the
MammaPrint assay, the patients can be divided into low- or high-risk
groups, corresponding to a 10-year distantmetastasis-free survival rate
of > 90% or < 90%, respectively.37 The TRANSBIG validation
study showed that patients classiﬁed as low risk using the Mam-
maPrint assay had a 10% chance of distant recurrence and those
classiﬁed as high risk a 29% chance of recurrence, without adjuvant
treatment at 10 years.49,50 Several studies have provided support for
the predictive power of MammaPrint for the response to adjuvant or
neoadjuvant chemotherapy.37 MammaPrint has a broader indication
thanOncotype DX by including both ERþ and ER patients and has
been approved by the FDA for use as a prognostic test for womenwith
lymph node-negative breast cancers.37,43 Unlike Oncotype DX,
however,MammaPrint is not currently approved as a predictive test of
chemotherapy beneﬁt. Further research is required to validate the
predictive capabilities of this test.
Using microarray and RT-PCR data, a 50-gene prediction
analysis of microarray (PAM50) assay was developed to provide a
standardized method of breast cancer classiﬁcation into the intrinsicsubtypes (luminal A, luminal B, HER2þ, and basal-like), together
with a continuous risk of recurrence score (based on the gene
signature, intrinsic subtype, tumor size, and proliferation score).51
A recent study found that the incorporation of selected prolifera-
tion and pathologic features that generate the risk of recurrence
score with the PAM50 assay provided more prognostic information
than the Oncotype DX Recurrence Score in patients with
endocrine-treated, ERþ, and node-negative disease, with fewer
patients categorized as intermediate risk and more as high risk.52
PAM50 can also identify which HER2þ breast cancers are most
likely to beneﬁt from trastuzumab-based chemotherapy.53 This
originally quantitative RT-PCR assay has now been developed by
NanoString Technologies into Prosigna, a DNA hybridization-
based assay that uses the PAM50 gene signature for the diagnosis
of the intrinsic subtype of breast tumors from FFPE tissue
samples.30 Prosigna has recently been approved by the FDA and
European, Australian, and Canadian marketing authorities as a
prognostic indicator for distant recurrence-free survival at 10 years
in postmenopausal women with HRþ breast cancer who have
undergone surgery in conjunction with locoregional treatment
consistent with the standard of care.54-56 However, it is important
to note that additional criteria for the Prosigna indication vary
between countries. The FDA-approved indication for Prosigna in
the United States is lymph node-negative stage I or II or lymph
node-positive stage II breast cancer.54 In Europe, Australia, and
Canada, Prosigna has been approved for use in lymph node-negative
stage I or II or lymph node-positive stage II or IIIA breast cancer to
be treated with adjuvant endocrine therapy alone, when used in
conjunction with other clinicopathologic factors.55,56
The IMPAKT 2012 working group evaluated the validity of 6
different prognostic genomic tests, including the Oncotype DX,
MammaPrint, PAM50, Genomic Grade Index (Ipsogen), Breast
Cancer Index (Biotheranostics), and EndoPredict (Sividon Di-
agnostics).29 Using available data, they found Oncotype DX and
MammaPrint to have convincing analytical validity and convincing
clinical validity in patients with ERþ breast cancer.29 The other tests
showed a clear association with prognosis, but the IMPAKT 2012
working group concluded that further data, including from larger
population sizes, was required for convincing clinical validity.29 None
of the tests provided convincing clinical utility. The IMPAKT 2012
working group reported that models need to be developed that inte-
grate the clinicopathologic factors and genomic tests.29 The European
Society for Medical Oncology Clinical Practice Guidelines for the
diagnosis, treatment, and follow-up of early breast cancer suggest that
gene expression proﬁle tests, including MammaPrint, Oncotype DX,
Prosigna, and EndoPredict, might be used to help make treatment
decisions in conjunction with all clinicopathologic factors, when de-
cisions might be challenging or in cases of uncertainty regarding in-
dications for adjuvant chemotherapy.57
Next-Generation Sequencing Technologies
Next-generation sequencing (NGS) can sequence an entire
genome (all DNA) or exome (coding gene regions) in 1 run to
proﬁle mutations, rearrangements, ampliﬁcations, or deletions
(DNA sequencing). NGS can also be used to analyze the entire
transcriptome (cellular RNA, RNA sequencing) to determine gene
expression levels, splicing patterns, and RNA editing as well as someClinical Breast Cancer June 2016 - 169
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170 -gene rearrangements and mutations. Such a broad approach enables
the discovery of new genetic abnormalities that can predispose to, or
characterize, a particular tumor type.
NGS technologies afford an unprecedented sequencing
depth (ie, the number of times a single base within the genome is
sequenced), enabling rare sequences to be detected.58 For instance, a
tumor that contains a large amount of normal tissue would require
greater sequencing depth to detect the tumor mutations. This is also
important for overcoming issues of tumor heterogeneity, in which a
particular clone might be especially underrepresented.
Slightly more targeted approaches can also be used in which
large panels (a few hundred) of cancer-speciﬁc genes are selec-
tively sequenced.59-61 These NGS panels require less total
sequencing and afford in-depth coverage for the genes of inter-
est.31 A range of NGS panels featuring different gene sets are
available, including those from companies such as Foundation
Medicine, Qiagen, Life Technologies, and Illumina, as well as
independent laboratories and academic institutions.31 A recent
study found that the use of an NGS panel for patients with solid
tumors, the most frequent being breast cancer (26% of patients),
identiﬁed potentially actionable alterations in most patients,
additional therapeutic options and facilitated enrollment into
clinical trials.62 NGS panels are also frequently used in explor-
atory analyses of genetic biomarkers in clinical trials.
NGS-based assays that can detect gene mutations from small
amounts of DNA are also in development; for example, to analyze
tumor DNA from ﬁne needle aspirates or circulating tumor DNA
(ctDNA) from blood samples.63-66 Several studies across various
tumor types have shown a high degree of concordance between
mutations in ctDNA (detected using NGS techniques) and muta-
tions from the primary tumors.63,64,66 In a study of 17 patients with
metastatic breast cancer, the Ion AmpliSeq Cancer Hotspot Panel,
version 2 (Ion Torrent) was used to analyze 69 tumor samples
(primary and metastases) and 31 plasma samples.67 Tumor and
plasma results were concordant in 76% of patients; complementary
information was provided by discordant results (24% of patients).67
A separate study of 6 patients with advanced breast, ovarian, and
lung cancer who were followed up for > 1 to 2 years demonstrated
that exome-wide analysis of ctDNA could identify the development
of resistant mutations to certain therapies, including mutations in
PIK3CA (after paclitaxel treatment), RB1 (after cisplatin treatment),
and EGFR (T790M; after geﬁtinib treatment).68 The
GUARDANT360 assay, a single-molecule next-generation digital
sequencing assay that detects mutations in ctDNA across a panel of
54 genes, has also demonstrated promising results using samples
from patients with breast cancer.69,70
The introduction of NGS and other high-throughput genome-
wide technologies into the clinical setting is set to signiﬁcantly alter
breast cancer diagnosis and management. However, certain obsta-
cles must be overcome before such technologies are incorporated in
routine clinical practice. The SAFIR01 trial, which tested the ability
of comparative genome hybridization arrays and Sanger sequencing
to guide therapeutic decisions in patients with metastatic breast
cancer, demonstrated limited clinical beneﬁt (9% objective response
and 21% stable disease) for inclusion of these techniques in
decision-making.71 NGS technologies generate a vast amount of
data, which require specialized storage, processing, and analysisClinical Breast Cancer June 2016programs that might not be easily implemented in small diagnostic
laboratories.72 Distinguishing between mutations that drive tumor
growth and development and other “passenger” mutations also
represents a challenge to clinical practice. Finally, ethical and legal
concerns regarding the protection of patients’ genetic information
need to be resolved before genome-wide technologies can be used in
the clinical setting.72
Biomarkers in Clinical Trials
The association between drug responsiveness and the presence of,
or change in, biomarkers is increasingly being tested across different
tumor types in clinical trials. This includes proof-of-concept trials,
which only enroll patients with speciﬁc biomarkers (integral bio-
markers); trials in which enrollment is stratiﬁed according to pres-
ence or absence of biomarkers; and trials that prospectively
investigate the effect of biomarkers on drug response from tissue
samples acquired during enrollment (integrated biomarkers).73
The incorporation of biomarkers into clinical trials aims to allow
more accurate identiﬁcation of patients who are likely to beneﬁt
from certain therapies and to provide a more comprehensive view of
how novel therapies work. However, introducing biomarkers into
clinical trials remains somewhat challenging, particularly owing to
the need for standardization of assays across multiple countries and
clinical practices. HER2 testing in clinical trials has been contro-
versial owing to the potential discordance between local and central
laboratories and between assay methods (IHC vs. FISH). For
example, a small subgroup of patients who were included in the
adjuvant National Surgical Adjuvant Breast and Bowel Project
(NSABP)-B31 trial on the basis of HER2þ status on local testing
were conﬁrmed to have HER2 status on central laboratory anal-
ysis.74 Despite central HER2-negativity, these patients showed a
signiﬁcant beneﬁt from trastuzumab, suggesting that adjuvant
trastuzumab might beneﬁt patients regardless of HER2 ampliﬁca-
tion status.74 The IHC assay results can be inﬂuenced by variations
in sample preparation, choice of antibody, and subjective assessment
of the staining intensity.75 Careful assay design and validation and
the collection of appropriate specimens are therefore required to
generate meaningful results from the inclusion of biomarker ana-
lyses in clinical trials. Tissue availability also poses a challenge for
incorporation of biomarkers into clinical trials. However, if such
challenges can be overcome, trials of this nature have the potential
to provide great value in terms of personalized medicine.
Examples of biomarker-driven clinical trials in breast cancer are
highlighted in Tables 3 and 4. I-SPY 2, a randomized trial with an
adaptive study design, is underway in the neoadjuvant setting. I-SPY
2 is investigating several different experimental treatment regimens
in women with newly diagnosed, locally advanced breast cancer at
high risk of disease recurrence.80 Patients are randomly assigned to
standard neoadjuvant chemotherapy or neoadjuvant therapy plus an
experimental regimen according to the patient’s tumor bio-
markers.80 Standard biomarkers (including intrinsic subtype classi-
ﬁcation and the MammaPrint assay) are used to determine patient
eligibility and randomization; predictive and exploratory biomarkers
will be evaluated during the trial.81 The adaptive trial design enables
early data from the trial to be used to guide treatment decisions for
patients later in the trial and minimize the exposure of patients to
treatments that will not beneﬁt them.80 In the metastatic setting,
Table 3 Examples of Biomarker-Driven Clinical Trials of Breast Cancer: PI3K/AKT/mTOR Pathway Inhibitors, PARP Inhibitors, and AR-
Targeted Therapy
Trial Name/ID Agent(s) Phase Patient Population Status
PI3K/AKT/mTOR Pathway Inhibitors
SANDPIPER; NCT0234022176 Fulvestrant  taselisib
(GDC-0032; Genentech/Roche;
beta-sparing PI3K inhibitor)
III Postmenopausal women with
unresectable, locally advanced
or metastatic ERþ, HER2,
PIK3CA-mutant breast cancer refractory
to an aromatase inhibitor; n z 600
Ongoing
SOLAR-1; NCT0243731876 Fulvestrant  alpelisib (BYL719;
Novartis; PI3Ka inhibitor)
III Men and postmenopausal
women with HRþ, HER2 advanced
breast cancer with identiﬁed PIK3CA
status and progression on or after
aromatase inhibitor treatment;
n z 820
Ongoing
BELLE-2; NCT0161028476,77 Fulvestrant  buparlisib
(BKM120; Novartis
Pharmaceuticals;
pan-PI3K inhibitor)
III Postmenopausal patients with locally
advanced or metastatic HRþ, HER2
breast cancer refractory to an
aromatase inhibitor; stratiﬁed by PI3K
pathway activation status (mutation in
the PIK3CA gene and/or loss of PTEN
expression by IHC); n z 1149
No longer recruiting
NCT0192316876 Letrozole  buparlisib (BKM120;
Novartis Pharmaceuticals;
pan-PI3K inhibitor) or alpelisib
(BYL719; Novartis
Pharmaceuticals; PI3Ka inhibitor)
II Postmenopausal women with HRþ,
HER2 primary breast cancer;
2 cohorts: PIK3CA
mutant and PIK3CA wild-type;
n z 360
Ongoing
BEECH; NCT0162528676 Paclitaxel  AZD5363
(AstraZeneca; AKT inhibitor)
I/II Advanced or metastatic breast cancer
(ERþ, HER2 in phase II part);
stratiﬁed by PIK3CA mutation status
in phase II part; n z 140
Ongoing
FAKTION; NCT0199295276 Fulvestrant  AZD5363
(AstraZeneca; AKT inhibitor)
I/II Postmenopausal women with advanced
ERþ, aromatase inhibitor-resistant
breast cancer; mutational status of
PIK3CA and loss of PTEN assessed at
baseline; n z 150
Ongoing
NCT0245791076 Taselisib (GDC-0032; Genentech/
Roche; b-sparing PI3K inhibitor) þ
enzalutamide (MDV3100;
Medivation; AR antagonist)
I/II Patients with ARþ TNBC;
n z 74
Ongoing
PARP inhibitors
NCT0216369476 Carboplatin and paclitaxel 
veliparib (ABT-888; AbbVie;
PARP inhibitor)
III Metastatic or locally advanced HER2
and unresectable breast cancer;
suspected deleterious or deleterious
BRCA1 and/or
BRCA2 germline mutation;
n z 270
Ongoing
EMBRACA; NCT0194577576 Talazoparib (BMN 673; BioMarin
Pharmaceutical; PARP inhibitor)
vs. physician’s choice
III Locally advanced and/or metastatic
breast cancer with deleterious or
pathogenic germline BRCA1 or
BRCA2 mutation;
n z 429
Ongoing
BRAVO; NCT0190559276 Niraparib (MK-4827; Merck;
PARP inhibitor) vs. physician’s
choice
III HER2 breast cancer; germline
BRCA1 or BRCA2 mutation;
n z 306
Ongoing
NCT0107497076 Cisplatin  rucaparib
(AG-014699; Clovis Oncology;
PARP inhibitor)
II Stage I-III TNBC after preoperative
chemotherapy; deleterious
BRCA1 or BRCA2 mutation;
nz 135
No longer recruiting
ICEBERG 1;
NCT0049423476
Olaparib (AZD2281, KU0059436;
AstraZeneca/KuDOS
Pharmaceuticals; PARP inhibitor)
II Advanced breast cancer after failure on
previous
chemotherapy; BRCA1 or
BRCA2 mutation; n z 81
No longer recruiting
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Table 3 Continued
Trial Name/ID Agent(s) Phase Patient Population Status
AR-targeted therapy
NCT0188923876,78 Enzalutamide (MDV3100;
Medivation; AR antagonist)
II ARþ TNBC; n z 118 No longer recruiting
NCT0209196076 Enzalutamide (MDV3100;
Medivation; AR antagonist) þ
trastuzumab
II Locally advanced or metastatic ARþ,
HER2þ, and ER/PR
breast cancer; n z 80
Ongoing
NCT0199020976 Orteronel (TAK-700; Takeda/
Millennium Pharmaceuticals;
androgen biosynthesis inhibitor)
II ARþ, metastatic breast cancer;
n z 86
Ongoing
NCT0236869176 Enobosarm (GTx-024; GTx, Inc.;
SARM)
II ARþ TNBC; n z 55 Ongoing
NCT0235398876 Bicalutamide (AstraZeneca Ltd.;
nonsteroidal antiandrogen) vs.
physician’s choice
II ARþ TNBC; n z 60 Planned
Abbreviations: AR ¼ androgen receptor; BRCA ¼ breast cancer susceptibility gene; ERþ/e ¼ estrogen receptor-positive/negative; HER2þ/e ¼ human epidermal growth factor receptor 2-positive/
negative; HRþ ¼ hormone receptor-positive; IHC ¼ immunohistochemistry; mTOR ¼ mammalian target of rapamycin; PARP ¼ poly (ADP ribose) polymerase; PIK3CA ¼ phosphatidylinositol 3-
kinase catalytic subunit alpha; PI3K ¼ phosphatidylinositol 3-kinase ; PRe ¼ progesterone receptor-negative; PTEN ¼ phosphatase and tensin homolog; SARM ¼ selective androgen receptor
modulator; TNBC ¼ triple-negative breast cancer.
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172 -the phase II SAFIR02 trial is using NGS of metastatic lesions from
patients with HER2 breast cancer to randomly assign patients to
receive the appropriate targeted therapy versus standard therapy.76
This follows from the SAFIR01 study that suggested the feasi-
bility of personalization of medicine for metastatic breast cancer.71
In the HRþ breast cancer arena, several biomarker-driven or
stratiﬁed clinical trials are being conducted to assess the efﬁcacy of
both well-established and pipeline PI3K pathway inhibitors in
speciﬁc patient populations and to elucidate mechanisms of resis-
tance (Table 3). The phase III BELLE-2 study is investigating
buparlisib (BKM120), a pan-PI3K inhibitor, combined with ful-
vestrant in postmenopausal women with locally advanced or met-
astatic HRþ, HER2 breast cancer refractory to an aromatase
inhibitor.76,77 Patients are stratiﬁed by PI3K pathway activation
status (mutation in the PIK3CA gene and/or loss of phosphatase and
tensin homolog expression by IHC) and visceral disease status.76,77
The ﬁrst results from this trial demonstrated that although the
median progression-free survival was only modestly improved by the
addition of buparlisib to fulvestrant for patients with PI3K pathway-
activated tumor tissue (6.8 vs. 4.0 months; hazard ratio, 0.76; P ¼
.014), patients with PIK3CA-mutant ctDNA derived meaningful
clinical beneﬁt (7.0 vs. 3.2 months; hazard ratio 0.56, P < .001).82
In part I of the phase II FERGI trial of fulvestrant combined with
the pan-PI3K inhibitor pictilisib (GDC-0941) or placebo in pa-
tients with ERþ, HER2 metastatic breast cancer,83 the response to
pictilisib was independent of tumor PIK3CA mutation status.83
Although a positive trend was seen toward improved progression-
free survival by the addition of pictilisib to fulvestrant overall, a
signiﬁcant improvement in progression-free survival was observed in
patients with tumors that were both ERþ and PRþ (hazard ratio,
0.46; 95% conﬁdence interval, 0.27-0.78); this improvement was
also independent of PIK3CA mutation status.83 In studies of neo-
adjuvant everolimus (an inhibitor of mammalian target of rapa-
mycin [mTOR] within the PI3K pathway), alone or combined with
letrozole, in ERþ breast cancer, biopsies obtained at baseline and
after 2 weeks of treatment were evaluated for PIK3CA mutationalClinical Breast Cancer June 2016status and pharmacodynamic changes.84-86 The results suggested
that tumors with PIK3CA exon-9 mutations, high Ki-67 (a marker
for proliferation), HER2-positivity, or high levels of phosphorylated
AKT, might beneﬁt from neoadjuvant everolimus therapy.
In HER2þ breast cancer, the effect of biomarkers on treatment
outcome was investigated as part of the phase III CLEOPATRA
(clinical evaluation of pertuzumab and trastuzumab) study, which
demonstrated improved efﬁcacy of the anti-HER2 monoclonal
antibody, pertuzumab, combined with trastuzumab and docetaxel
versus placebo plus trastuzumab and docetaxel in the ﬁrst-line
treatment of patients with HER2þ metastatic breast cancer.87
Prospective biomarker analysis of CLEOPATRA revealed that
elevated HER2 protein, high HER2 and HER3 mRNA levels,
wild-type PIK3CA, and low serum HER2 extracellular domain
showed a signiﬁcantly better prognosis, with PIK3CA showing the
greatest prognostic effect.87 Therapy targeting ARs is also being
studied in HER2þ breast cancer; therefore, some clinical trials are
testing for AR status. For example, a phase II trial of enzalutamide
(an AR antagonist) combined with trastuzumab is being investi-
gated in locally advanced or metastatic breast cancer that is
HER2þ, ARþ, and ER.76
Molecular biomarkers are also being used for patient selection in
trials of triple-negative breast cancer (TNBC; ER, PR, and
HER2). TNBC is a heterogeneous disease, and a recent study
identiﬁed 6 distinct TNBC subtypes.88 A proportion of TNBCs
are characterized by defective BRCA-dependent homologous
recombination. These tumors appear to be responsive to agents that
lead to DNA double-strand breaks, such as platinum salts and poly
(ADP-ribose) polymerase inhibitors.89 Identiﬁcation of tumors with
BRCA-dependent homologous recombination classically involved
identifying germline mutations in the BRCA1 or BRCA2 genes.
Recently, gene signatures that suggest inactivation of homologous
recombination in breast tumors in the absence of BRCA1 or BRCA2
germline mutations, termed BRCAness, have been developed.89 In a
recent clinical trial, patients with tumors classiﬁed as BRCA-like
by array comparative genomic hybridization were found to have a
Table 4 Examples of Biomarker-Driven Clinical Trials of Breast Cancer: Tyrosine Kinase Inhibitors, Immunotherapy, and Molecular
Target-Driven Trials
Trial Name/ID Agent(s) Phase Patient Population Status
TKI
NCT0152834576,79 Dovitinib (TKI-258; Novartis Pharmaceuticals;
FGFR, VEGFR, and PDGFR inhibitor)
plus fulvestrant
II Postmenopausal patients with locally advanced
or metastatic HRþ, HER2 breast cancer;
progression during or after endocrine treatment;
stratiﬁed by FGF ampliﬁcation and
visceral disease; n z 97
Completed
NCT0148404176 Dovitinib (TKI-258; Novartis Pharmaceuticals;
FGFR, VEGFR, and PDGFR inhibitor) plus an
aromatase inhibitor
I/II HRþ, HER2 breast cancer (primary or
metastatic) resistant to an aromatase inhibitor;
tumor must be available for central testing for
FGFR1 ampliﬁcation;
n z 36
No longer
recruiting
NCT0220274676 Lucitanib (Clovis Oncology;
FGFR, VEGFR, and PDGFR
inhibitor)
II Relapsed or refractory
metastatic breast cancer;
different cohorts based on
FGFR1 or 11q ampliﬁcation;
n z 201
Ongoing
FINESSE; NCT0205363676 Lucitanib (Clovis Oncology;
FGFR, VEGFR, and PDGFR
inhibitor)
II Metastatic ERþ breast cancer
after hormonal therapy; different cohorts based
on FGFR1 or 11q ampliﬁcation; n z 123
Ongoing
RADICAL; NCT0179198576 AZD4547 (AstraZeneca; FGFR inhibitor) plus
letrozole or anastrozole vs. exemestane
I/II ERþ breast cancer (primary or metastatic);
progression on anastrozole or letrozole;
mandatory tumor biopsy for conﬁrmation of
FGFR1 status by FISH for phase IIa; n z 56
Ongoing
Immunotherapy
PANACEA; NCT0212955676,93 Pembrolizumab (MK-3475; Merck; PD-1
monoclonal antibody) plus trastuzumab
Ib/II Advanced, trastuzumab-resistant, HER2þ breast
cancer; presence of PD-L1 expression as
assessed by IHC; n z 46
Ongoing
METRIC; NCT0199733376 Glembatumumab vedotin (CDX-011; Celldex
Therapeutics; anti-gpNMB antibody) vs.
capecitabine
II Metastatic gpNMB-overexpressing TNBC;
n z 300
Ongoing
NCT0182802176 Margetuximab (MGAH22; MacroGenics;
anti-HER2 antibody)
II Relapsed or refractory advanced breast cancer
that is HER2þ by IHC with no HER2 gene
ampliﬁcation by FISH; n z 41
Ongoing
NCT0067382976 Anti-CEA designer T cells  interleukin-2 I Metastatic or unresectable locally advanced
breast cancer with
CEA expression; n z 26
No longer
recruiting
NCT0234972476 Anti-CEA designer T cells I Relapsed or refractory CEAþ
lung, pancreatic, gastric, breast,
or colorectal cancer; n z 75
Ongoing
NCT0183760276 cMet CAR RNA T Cells I Metastatic breast cancer
refractory to 1 standard
therapy or newly diagnosed operable TNBC,
both with positive cMET expression;
n z 15
Ongoing
Molecular target-driven trials
I-SPY 2; NCT0104237976 Experimental: AMG 386,
ganitumab (AMG 479), MK-2206, T-DM1,
pertuzumab, trastuzumab, ganetespib
II Invasive cancer of the breast,
with no previous chemotherapy
or radiation therapy; patient is assigned to a
treatment arm
after tumor molecular proﬁling;
n z 1200
Ongoing
SAFIR02; NCT0229999976 Experimental: AZD2014,
AZD4547, AZD5363, AZD8931, selumetinib,
vandetanib, bicalutamide, olaparib
II Metastatic, relapsed, or stage IV HER2 breast
cancer with 2
lines of previous chemotherapy; patient is
assigned to a treatment arm after tumor
molecular proﬁling; n z 460
Ongoing
Abbreviations: CAR ¼ chimeric antigen receptor; CEA ¼ carcinoembryonic antigen; CTA ¼ cancer-testis antigen; ER ¼ estrogen receptor; FGFR ¼ ﬁbroblast growth factor receptor;
FISH ¼ ﬂuorescence in situ hybridization; gpNMB ¼ glycoprotein NMB; HER2þ/e ¼ human epidermal growth factor receptor 2-positive/negative; HRþ ¼ hormone receptor-positive; IHC ¼
immunohistochemistry; PD-1 ¼ programmed cell death protein 1; PDGFR ¼ platelet-derived growth factor receptor; PD-L1 ¼ programmed cell death ligand 1; poly-ICLC ¼ polyinosine/cytosine
stabilized with poly-L-lysine and carboxymethylcellulose; TKI ¼ tyrosine kinase inhibitor; TNBC ¼ triple-negative breast cancer; VEGFR ¼ vascular endothelial growth factor receptor.
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174 -signiﬁcantly better overall survival with adjuvant high-dose cyclo-
phosphamide/thiotepa/carboplatin treatment versus conventional 5-
ﬂuorouracil/epirubicin/cyclophosphamide chemotherapy (adjusted
hazard ratio 0.19; 95%conﬁdence interval 0.08-0.48).90 Althoughno
targeted therapies are currently approved for the treatment of TNBC,
various agents targeting DNA damage and AR pathways are under
investigation76,91 (Table 3). In a phase II trial of enzalutamide in
patients with TNBC, median progression-free survival varied
depending on the level of ARþ staining (14 weeks in patients with
tumors with > 10% staining vs. 8 weeks in those with < 10%
staining).78,92 In the same study, an AR-related gene signature for
AR-positivity, PREDICT-AR, was found to predict clinical beneﬁt in
response to enzalutamide (clinical beneﬁt rate of 40% [ARþ] vs. 11%
[AR]).78,92 Enzalutamide combined with the PI3K inhibitor, tase-
lisib, is also being investigated in a phase I clinical trial of ARþTNBC.
In that trial, therapy-induced changes in biopsy analyses and RNA-
sequencing gene expression analyses will be evaluated in addition to
standard measurements of efﬁcacy and safety (ClinicalTrials.gov
identiﬁer, NCT02457910).76
Immunotherapy is also under investigation for the treatment of
TNBC and other types of breast cancer. For example, the pro-
grammed cell death protein 1 (PD-1) antibody, pembrolizumab
(MK-3475), is being investigated in patients with advanced,
trastuzumab-resistant, HER2þ breast cancer positive for pro-
grammed cell death ligand 1 expression, in the phase Ib/II
PANACEA (anti-PD-1 monoclonal antibody in advanced,
trastuzumab-resistant, HER2þ breast cancer) trial (Table 4).76,93
In addition, immune-related gene signatures and measures of
tumor-inﬁltrating immune cells are under investigation and could
become integrated into patient selection for clinical trials.94,95
The immunoscore records the abundance of 2 lymphocyte pop-
ulations (CD3/CD45RO and CD3/CD8 or CD8/CD45RO) in
the tumor core and at its invasive margins and could identify
patients likely to beneﬁt from immunotherapy and/or certain
chemotherapies.94-96 Although further validation is required, the
advent of such immune scores and the expanding use of bio-
markers in patient selection for targeted therapies means the role
of the pathologist in clinical trials of breast cancer is ever
increasing.
Role of the Pathologist
Our enhanced understanding of the molecular concepts under-
lying the etiology of breast cancer and the advent of targeted thera-
peutics and personalized medicine has meant that the role of
pathologists in breast cancer trials has changed considerably. During
the past decade, the role of the pathologist has shifted from that of
tumor diagnosis and histologic classiﬁcation97 toward more func-
tional pathology, including the identiﬁcation of biomarkers of ther-
apeutic response and new targets for therapy.98 Pathologists are now
involved in various stages of clinical trials, from pretrial/eligibility
screening through to the determination of response to therapy.
In clinical trials of breast cancer, pathologists are required for
determining the molecular proﬁle of a tumor. In addition to clas-
sifying the tumor into one of the main subtypes according to the
HR and/or HER2 status, trials of targeted therapy often require
testing for other speciﬁc molecular markers (eg, markers of PI3K
pathway activation, BRCAness, or mutations in growth factorClinical Breast Cancer June 2016receptors). These molecular markers can be prerequisites for
enrollment or can be used for patient stratiﬁcation before
randomization. An equally important role for pathologists lies in
quality control and ensuring the correct technologies are applied. To
this end, centralized testing of HER2 is typically used in clinical
trials of anti-HER2 agents to ensure consistency across centers.
Pathologists also have a critical role in assessing the primary
endpoints. The pathologic complete response (pCR), deﬁned as the
absence of residual disease after surgery, is a common endpoint in
neoadjuvant trials and is assessed by the pathologist. CAP has
provided guidelines to assist pathologists in reporting the exami-
nation of breast specimens at surgery.99 The exact deﬁnitions of
pCR can vary considerably and little, if any, agreement has been
reached regarding the precise deﬁnition of this endpoint. In a study
of > 6000 patients from 7 prospectively conducted clinical trials of
neoadjuvant anthracycline and taxane-based chemotherapy, the
pCR deﬁnition of no residual invasive or in situ cancer within both
the breast and the lymph nodes has been shown to be associated
with longer disease-free and overall survival than the absence in the
breast alone or the presence of residual ductal carcinoma in situ
(DCIS).100 In contrast, another study reported that residual DCIS
did not adversely affect the outcomes and therefore did not appear
to be prognostic.101 The investigators of the latter study argued that
residual DCIS should be included in the deﬁnition of a pCR.101
Pathologists also play a critical role in determining the effect of
biomarkers or molecular alterations on response to therapy and in
monitoring the markers of response to determine the effectiveness of
therapy. Different tissues, including peripheral blood mononuclear
cells, platelet-rich plasma, skin, and hair, are under investigation as
surrogates for tumor tissue102 and can be used by pathologists to
assess the pharmacodynamic effects of anticancer agents in clinical
trials. Such tissues are readily available, easily accessible, and can be
sampled repeatedly with limited invasiveness. In addition,
circulating tumor cells (CTCs) can be isolated from blood and
potentially serve as a “liquid biopsy.”103 Studies have demonstrated
that a change in the number of CTCs can be an early marker of
response to therapy, and their molecular characterization can be
representative of the current tumor molecular status.103 However,
the predictive ability of CTC biomarker analysis has demonstrated
variable and inconclusive results.104 Reports from the HER2þ
metastatic setting have indicated that CTC counts can lose their
prognostic signiﬁcance after treatment with HER2-directed ther-
apy.105,106 Furthermore, anti-HER2 or anti-epidermal growth fac-
tor receptor (EGFR) treatment in patients with HER2þ or EGFRþ
CTCs (who had HER2 primary tumors) has been associated with
limited or no response.107-109 Additional studies are therefore
necessary before CTC analyses can be introduced into clinical
practice. Tumor cells also release nucleic acids into the bloodstream,
and ctDNA might reﬂect the molecular characteristics of the pri-
mary tumor.110 The use of ctDNA has demonstrated signiﬁcant
sensitivity in monitoring tumor progression and early tumor
responsiveness to therapy in metastatic breast cancer.111
Overall, pathologists have an essential and varied role in all stages
of breast cancer clinical trials. Pathologists can therefore provide
important input into clinical trial designs and should be involved in
the process as early as possible. Pathologists can advise on the type of
tissue collected, the techniques used, and the deﬁnition of
Hyo Sook Han, Anthony M. Maglioccoendpoints, all of which can depend on the type of trial and sample
availability. Failure to include the pathologist in clinical trial pro-
tocol development can result in less suitable investigations and an-
alyses, a potential need to retest tumor samples, and, ultimately, a
delay in patients receiving treatment.
Considerations for Pathologists
The availability of adequate tissue samples represents a major
challenge in clinical trials, particularly in the retrospective setting,
where access and retrieval of tissue samples and the degradation of
specimens over time can hinder the analyses.112 Moreover, signiﬁ-
cant legal and ethical considerations exist relating to ownership of
the archival tissue material that must be considered. Although it is
clear how tissue samples should be used in clinical trials using in-
tegral biomarker testing (eg, determining HER2 status for patient
enrollment), the procedures and regulations involved in the retrieval
and use of samples for post-trial biomarker analyses are more
complex. Clarity is lacking regarding who owns the specimens and
for what purposes the specimens can be used, and informed consent
for further use of tissue samples is often required from patients.113
In addition, considerable disparity exists among the hospitals and
governing authorities in how these specimens can be managed.113
For some institutions, the decision remains with the patient, and
for others, it lies with the laboratory; this presents a unique chal-
lenge in multicenter clinical trials. In the event of competing trials
requiring the same tissue specimens, the lack of clear guidance also
generates an ethical challenge for the laboratory when trying to
prioritize how and for which trials the tissue specimens can be used.
All these considerations can lead to delays in the analysis of archival
tumor samples and, thus, delays in clinical trial enrollment and
treatment administration.
It should also be determined whether repeat diagnostic processes
will be performed on tissue received by the pathologist. Pathologists
might automatically perform their own diagnosis if they are unaware
that a diagnosis had been previously established or if they believe
they are liable for providing their own diagnosis if they have not had
the opportunity to review the previous results. Such repeat diag-
nostic processes can leave limited material for molecular testing.114
Moreover, pathologists might wish to perform their own testing
regardless of the previous results owing to the critical nature of
accurate pathology reporting. Conﬁrmation of a diagnosis or bio-
logic marker through repeat assessment of tissue is essential to
ensure correct and appropriate treatment decisions are being made.
In addition, an error in the pathology report could lead to the
incorrect entry of a patient into a clinical trial. Should a discrepancy
in the diagnoses be found, this can also have malpractice implica-
tions, and the legal implications surrounding these issues need
careful consideration.
Prospective studies might allow the collection of tissues according
to the protocols; however, proper diagnostic processing might limit
sample availability for exploratory analyses.112 Furthermore, effec-
tive communication between clinicians and pathologists is critical
for determining the type of sample to be collected, the method for
sample processing, and the downstream tests that are required,
which all depend on the nature of the clinical trial. It is also
important to consider whether the samples will be processed “in
house” or will be sent externally for the management of the tissuesamples and handling steps. Furthermore, a wide array of technical
challenges exists for tissue preservation and sample prepara-
tion.115,116 Fixation procedures can cause damage to the genomic
DNA, and variability in these procedures is likely to affect the re-
sults.117 Although formalin-based ﬁxation is thought to be the
reference standard,112 delays in formalin ﬁxation have been shown
to impede HR and HER2 analysis, and brief ﬁxation followed by
rapid processing has proved effective for ER IHC in core biopsy
specimens.115,116 The ASCO/CAP guidelines have recommended
that any specimen used for HER2 testing should undergo the ﬁx-
ation process as soon as possible within 1 hour and ﬁxed
in 10% neutral buffered formalin for 6 to 72 hours. The time to
ﬁxation and the time in the ﬁxative should also be recorded.33
Other factors that affect tissue preservation include intraoperative
ischemia and hypoxia, previous biopsy, type of ﬁxative used, and
method of parafﬁn block preparation.112 Although the use of fresh
or frozen tissue samples can overcome many of these issues and
generally yield high-quality DNA, these techniques are costly and
not always feasible.112,117 The optimization and standardization of
these procedures will help improve the quality of tissue available for
clinical research. In addition, developing a tissue bank, in which the
remaining tumor tissue that has been removed during surgery or
biopsy can be stored, could prove beneﬁcial and ensure the avail-
ability of samples for future testing.112
Other factors to consider are the rates of concordance among
different techniques, specimens, and testing centers.117-119 In the
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment
Optimisation) trial, different assays demonstrated variability in the
detection of HER2 and ER status that was evident even at the
central testing centers.118 Discordance between assays can have
detrimental effects on treatment and clinical trial enrollment,
resulting in failure to treat a patient who might beneﬁt from tar-
geted therapy or the unnecessary treatment (with the associated
costs and safety implications) of a patient. A comparison of local and
central testing of HER2 status in a substudy of the VIRGO trial
revealed discordance between testing centers in the identiﬁcation of
HER2 positivity in the study.119 This supports the ASCO/CAP
recommendations to retest HER2 cases in certain situations,
coupled with close communication between pathologists and cli-
nicians.33,119 The HER2 gene is located in the long arm of chro-
mosome 17 and polysomy of chromosome 17 can also affect HER2
testing.32,120 Polysomy of chromosome 17 can result in discordant
HER2 testing by ISH, depending on whether the mean HER2 copy
number or the HER2/CEP17 ratio is used.120 In addition, the
regulation and effect of HER2 expression could differ between cases
of selective HER2 ampliﬁcation and an increase in copy number of
part or all of chromosome 17.120 Tumor purity is another impor-
tant consideration for molecular testing. Low tumor purity from
admixture with stromal, vascular, or inﬂammatory cells can dilute
the relevant biomarkers and promote false-negative results by
decreasing assay sensitivity.117
Different regulations for diagnostic testing could also be in place,
and, in Europe, local regulations for diagnostic testing can differ
between countries. In addition to the US FDA, another regulatory
body governing diagnostic tests in the United States is the Clinical
Laboratory Improvement Amendments program.121 Clinical Lab-
oratory Improvement Amendments regulates laboratory developedClinical Breast Cancer June 2016 - 175
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176 -tests (LDTs) in the United States, which are tests designed, man-
ufactured, and used within a single laboratory.121,122 However,
compared with the FDA scheme, the analytical validity of the
Clinical Laboratory Improvement Amendments program is limited
to the speciﬁcations of the particular laboratory where the test is
performed and does not address the clinical validity or the relevance
of the test.121 Although the FDA currently regulates only
commercially marketed laboratory tests, the increasing complexity
and widespread use of LDTs has led to the FDA proposing to
regulate LDTs under guidelines similar to those for commercially
marketed tests.122,123 This proposal is still under discussion among
the authorities, industry, and academia.123
A further important consideration is tumor heterogeneity, which
can lead to false-negative results and, thus, treatment failure and drug
resistance.117,124,125 The high proliferation rate of tumor cells,
combined with genomic instability and increased mutation rates, a
common feature of tumor cells, promotes substantial genetic diver-
siﬁcation of tumor cell populations.125 This can result in intratumor
heterogeneity, such that a single tumor biopsy specimenmight not be
representative of the entire tumor.125 Furthermore, intratumor het-
erogeneity and Darwinian selection of driver mutations that poten-
tially confer a growth or survival advantage can facilitate clonal
succession and lead to treatment failure.124,125 This also means that
archival tumor samples might not reﬂect the current molecular status
of the tumor. Similarly, the accumulation of molecular alterations
over time, known as tumor evolution/adaptation, presents a challenge
when relying on archival tumor samples.125,126 Emerging techniques
for analyses of CTCs or ctDNA could provide a less invasive approach
to sampling the present tumor molecular proﬁle.103,110 Metastasis of
the tumor to other sites also often involves molecular changes that
transform tumor cells into an aggressive form.127 Therefore, tumor
heterogeneity can exist between primary and secondary or metastatic
tumors. A signiﬁcant proportion of regional or distant breast cancer
relapse cases have been shown to exhibit changes in either ER or
HER2 status from the primary tumor, which would have a dramatic
impact on therapeutic strategy.128 The ASCO/CAP guidelines have
recommended evaluation of HER2 status in all patients with newly
diagnosed breast cancer and on metastases, in a metastatic site, if a
tissue sample is available.33
Overall, pathologists must consider multiple variables such as tu-
mor purity and heterogeneity and need to keep abreast of new tech-
nologies and updated procedures. Therefore, continuing medical
education is particularly important, and pathologists should receive
regular updates on this rapidly changing ﬁeld. Furthermore, it is
essential that all pathologists are properly educated regarding each
clinical trial they are involved in, including the purpose, protocol,
types of analyses required, and the questions under investigation. In
return, pathologists must make every endeavor to guarantee the ac-
curacy of molecular-based tests by ensuring appropriate specimen
collection and tissue handling before an assay is performed, by the
timely communication of results, and/or by reviewing and correlating
the results with the clinicians; all of which are reliant on good
communication between the pathologist and clinician.
Optimizing Pathology Practices
The ﬁeld of molecular testing in breast cancer is fast expanding,
with the addition of new technologies and procedures for sampleClinical Breast Cancer June 2016preparation and analysis. The development of comprehensive
guidelines and implementation of routine training practices for the
collection and processing of tissue samples is therefore critical, and
laboratory tests are now coming under closer scrutiny by the FDA.
Different trials often have different requirements for the preparation
and analysis of tissue samples; thus, the specimen types and analytic
methods for each trial should be independently assessed and care-
fully considered.
Developing processes that accelerate and prioritize molecular
testing will play a key role in improving the outputs of clinical
trials. To this end, a fundamental need exists to improve
communication between the oncologist and pathologist and to
increase coordination between teams. It is pertinent that pathol-
ogists are provided with sufﬁcient information about the requested
tumor samples to be able to perform the procedures using the
most effective method. The use of pathology in clinical trials can
be further optimized if the pathologist is involved early on in the
development of the trial protocol, including developing the study
design and determining patient eligibility, patient stratiﬁcation,
quality control, treatment evaluation, and the use of bio-
markers.129 Issues, such as tissue banking and prospective or
retrospective biomarker development, also need to be addressed
during clinical trial design.129
Conclusion
In this new era of molecular testing and personalized medicine,
the role of the pathologist in clinical trials of breast cancer is
changing. Recent advances in molecular analyses of breast tumors
have revealed differential molecular properties that affect the prog-
nosis, responsiveness, and resistance to therapy. The importance of
molecularly proﬁling breast tumors has meant that a multitude of
high-throughput assays and techniques are now entering clinical
practice. These techniques have shown promise in enhancing the
quantity and quality of information that can be obtained from
clinical trials and might overcome some of the challenges of tradi-
tional assays. To improve the outcomes for patients with breast
cancer, clinical trials must increasingly be designed to involve the
use of biomarkers in patient selection, as surrogate endpoints for
clinical response, to identify suitable patient populations for ther-
apy, and/or to determine the mechanisms of resistance. Thus, the
role of the pathologist in clinical trials has become complex and
varied. In addition to diagnosis, the pathologist must manage
complex testing and information, provide stewardship to the tissues,
coordinate data from multiple laboratories, and generate compre-
hensive reports. It is clear that the pathologist should be involved in
multiple stages during clinical trial development, including study
design and data analysis. The lack of consultation with the
pathologist can lead to delays or errors in sample processing and
ultimately delays in patients receiving treatment. With the
continuing evolution of molecular technologies, the pathologist is
set to play a pivotal role in both drug discovery and the clinical
treatment of patients with breast cancer.Acknowledgments
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